Shire (SHPG) & BioLife Solutions (BLFS) Financial Survey

Shire (NASDAQ: SHPG) and BioLife Solutions (NASDAQ:BLFS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Shire and BioLife Solutions, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shire 0 6 8 0 2.57
BioLife Solutions 0 0 2 0 3.00

Shire currently has a consensus target price of $212.18, indicating a potential upside of 35.30%. BioLife Solutions has a consensus target price of $6.50, indicating a potential upside of 1.88%. Given Shire’s higher possible upside, analysts plainly believe Shire is more favorable than BioLife Solutions.

Dividends

Shire pays an annual dividend of $0.92 per share and has a dividend yield of 0.6%. BioLife Solutions does not pay a dividend. Shire pays out 17.3% of its earnings in the form of a dividend.

Insider and Institutional Ownership

20.2% of Shire shares are owned by institutional investors. Comparatively, 9.4% of BioLife Solutions shares are owned by institutional investors. 2.0% of Shire shares are owned by insiders. Comparatively, 36.8% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Shire and BioLife Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Shire 10.95% 14.41% 6.60%
BioLife Solutions -52.10% -49.92% -29.47%

Volatility & Risk

Shire has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Earnings and Valuation

This table compares Shire and BioLife Solutions’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Shire $11.40 billion 4.14 $327.40 million $5.31 29.53
BioLife Solutions $8.23 million 10.57 -$6.87 million ($0.42) -15.19

Shire has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Shire, indicating that it is currently the more affordable of the two stocks.

Summary

Shire beats BioLife Solutions on 12 of the 16 factors compared between the two stocks.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

About BioLife Solutions

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

What are top analysts saying about Shire? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit